August 1, 2017
Mumbai, Maharashtra, India
Anemia remains a major global public health problem with nearly 2.3 billion people suffering from it – an estimated 50% due to iron deficiency anemia (IDA). Southeast Asia and Africa continue to have the highest prevalence of anemia – accounting for 85% of the burden affecting mainly women and children.
The situation has spurred international leading experts on iron and blood health, together with medical practitioners, to hold Anemia Convention 2017, the first scientific symposium on anemia spearheaded by global healthcare company Merck.
The July 7-8 convention held at The Peninsula Hotel, Manila in Makati City drew over a hundred participants from Indonesia, India, Malaysia, Sri Lanka, Vietnam, Singapore and the Philippines while renowned experts from Canada, Austria, Germany, and Australia flew in to discuss growing concerns over anemia especially since it continues to be one of the most pressing health issues in Asia. In fact, The World Health Assembly has adopted a comprehensive implementation plan to achieve six global nutrition targets with one of the specific aims being to achieve a 50% reduction in the rate of anemia in women of reproductive age by 2025.
Prof. Zulfiqar Ahmed Bhutta, Chair in Global Child Health at the Hospital for Sick Children, Toronto as well as Founding Director of the Centre of Excellence in Women and Child Health, at the Aga Khan University and keynote lecturer in the Anemia Convention, noted the staggering statistics on anemia and its prevalence in Asia.
“When you look at the maps of the distribution patterns of anemia, in infants and children from the most recent estimates that we have, it’s not too difficult to see that the vast majority of the world’s regions affected are the regions we are sitting in – South Asia, South Central Asia and Southeast Asia, also Africa,” Prof. Bhutta began.
“In numeric terms, if you look at women of reproductive age between 15 and 49, the figure becomes a little bit more dramatic. In Southeast Asia, there are 202 million affected women with anemia and in Western Pacific, about 100 million. 41.8% of pregnant women and almost 600 million preschool and school-age children globally are anemic whereof nearly 60% of pregnant and around half of children cases are attributable to iron deficiency,” he continued.
Prof. Bhutta cited The Institute for Health Metrics and Evaluation (University of Washington): The Global Burden of Diseases, Injuries and Risk Factors (GBD) 2010 Study showed that at a global level and between 1990 and 2010, the burden that the world has with concomitant iron deficiency anemia and related to nutritional factors remains large. Iron deficiency is the most common nutrient deficiency globally with approximately 4-5 billion people suffering from it.
As WHO states, “…it constitutes a public health condition of epidemic proportions.”
Data on global anemia trends also showed that between 1995 and 2013, there has been no dramatic change on anemia statistics despite the range of interventions. This is seen to be attributable to nutritional anemia.
The Anemia Convention stated that both iron deficiency (ID)) and IDA are the major challenges in Asia.
“Having an Anemia Convention is extremely important because anemia and iron deficiency are extremely common. In India, there is a need to do more than what is being done by the government and also when it comes to patient education,” Dr. Dhara Shah, Associate Director for Medical Affairs at Merck Group India, noted.
Merck, a leading science and technology company in healthcare, life science and performance materials, spearheaded the Anemia Convention 2017 to provide a platform for healthcare professionals to share their expertise, exchange views and discuss about the impact of ID and IDA on quality of life and on trends on iron supplementation in the context of anemia. The Convention likewise serve as an educational springboard for participants to take the learnings back to their markets and cascade them to their fellow Health Care Professionals to further build understanding and awareness.
“Merck is committed to the education and awareness around Anemia. Iron Deficiency Anemia is a burden that is regionally most importantly in Asia and Africa. For us, it’s an important area to look at. In these meetings, we’d like to connect with experts and healthcare professionals so we can learn about the disease, the diagnosis, the available treatments and about the gaps to be able to develop strategies and help healthcare professionals to deal better with this major public health burden,” Hans Griek, Chief Medical Officer, Merck Consumer Health said.
Iron deficiency anemia, if left untreated significantly impacts quality of life and life expectancy. It was the leading cause of years lived with disability among children and adolescents and is associated long-term with reduced working performance, cognitive impairment, and fatigue. Merck intends to address this global burden by being a key player in promoting overall blood health to combat iron deficiency anemia and help alleviate its impact. Merck’s support of medical education, one of which is through the Anemia Convention, complements the company’s We100 purpose which aims to help prepare society for a new era where people live healthier and longer—well beyond 100 years.
About Consumer Health Business of Merck
Brands of the Consumer Health business, such as Neurobion®, Dolo-Neurobion®, Bion®, Seven Seas®, Nasivin®, Femibion® and Sangobion® are innovative leaders in key markets, backed by science and trusted by consumers worldwide. The Consumer Health business is with over 2,600 employees globally active in over 40 markets. Since 2014, the portfolio comprises of brands with annual total sales of about $ 1 billion. Consumer Health is a business of the Healthcare business sector within the Merck Group with global headquarters in Darmstadt, Germany. For more information please go to www.meck-consumer-health-com as well as to https://twitter.com/merck_ch.
Merck is a leading science and technology company in the healthcare, life science and performance materials sectors. Around 50,000 employees work to further develop technologies that improve and enhance life—from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphone and LCD televisions. Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, Millipore Sigma and EMD Performance Materials.